N/A N=80 Registry For Patients Treated With BeneFix In Usual Care Setting In Germany
Hemophilia B
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 19; 49; 8; 29 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Phase 2 N=10 Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary Arterial Hypertension
Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…
N/A N=201 FOLCROM Trial: Foley Catheter in Rupture of Membranes
Premature Rupture of Membranes
Primary: Time From Induction of Labor Until Delivery — 14.4; 13.9 hours
Phase 4 N=3,939 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea
Meningococcal Disease
Primary: Number of Subjects Reporting Any Local and Systemic Solicited Adverse Events (AEs) — 67; 32; 28; 110 Participants
Phase 3 N=513 Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2
Infertility
Primary: Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation…
Phase 2 N=346 HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Percentage of Subjects With no Heavy Drinking Days (PSNHDD) — 17.3; 24.1 percentage of subjects with NHDD
N/A N=3,635 Pletaal SR Post Marketing Observational Study
Ischemic Symptoms · Cerebral Infarction
Primary: The Incidence Rate and the Number of AE/ADRs — 446; 155 Participants
N/A N=381 Statin Discontinuation in Advanced Illness
Palliative Medicine · Cardiovascular Disease
Primary: Proportion of Deaths Within 60 Days of Enrollment. — 0.203; 0.238 proportion of deaths
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 1 N=189 Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 2405.6; 2435.5; 2422.6 μg·h/mL
Phase 3 N=34 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Primary Sclerosing Cholangitis
Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants
N/A N=2,695 Screening and Brief Advice to Reduce Teen Substance Use
Substance Related Disorders
Primary: Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA — 162; 121 Participants — p=< 0.05
N/A N=24 Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block
Prostate CA
Primary: Time to First Request of Additional Analgesia
N/A N=13,381 Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk
Hypertension · Hyperlipidemia · Diabetes
Primary: Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke — -0.59; 1.66 annualized change in 10 year % cv risk — p=<0.05